HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Immunocore Holdings (NASDAQ:IMCR) and maintained a price target of $100.
August 28, 2024 | 10:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Immunocore Holdings and maintained a price target of $100, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $100 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Immunocore Holdings' future performance. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100